Exclusive license via Yeda to two Weizmann Institute patent families from Prof. Nir London’s lab, a leader in covalent drug design Site-specific, durable and traceless protein radiolabeling approaches intended to enhance tumor selectivity and retention in radiopharmaceuticals Integration into Actithera’s platform to support design of next-generation radioligand therapies across oncology indications Cambridge, MA and Oslo, […]